885275-10-5

Basic information

• Product Name: PYRAZOLO[1,5-A]PYRIDINE-2-CARBALDEHYDE
• Synonyms: H-pyrazolo[1,5-a]pyridine-2-carbaldehyde;Pyrazolo[1,5-a]pyridine-2-carboxaldehyde;1H-Pyrazolo[1,5-a]pyridine-2-carbaldehyde
• CAS NO: 885275-10-5
• Molecular Formula: C₈H₆N₂O
• Molecular Weight: 146.15
• Mol File: 885275-10-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.24
• Refractive Index: 1.64
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: PYRAZOLO[1,5-A]PYRIDINE-2-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: PYRAZOLO[1,5-A]PYRIDINE-2-CARBALDEHYDE(885275-10-5)
• EPA Substance Registry System: PYRAZOLO[1,5-A]PYRIDINE-2-CARBALDEHYDE(885275-10-5)

Safety Data

• Hazardous Substances Data: 885275-10-5(Hazardous Substances Data)

Usage

General Description

PYRAZOLO[1,5-A]PYRIDINE-2-CARBALDEHYDE is a chemical compound that belongs to the pyrazole family. It is an aldehyde derivative with a pyridine ring, and its molecular structure consists of a pyrazolo ring fused to a pyridine ring with a carbonyl group attached to the second carbon atom. PYRAZOLO[1,5-A]PYRIDINE-2-CARBALDEHYDE is used in various organic synthesis reactions and as a building block in the production of pharmaceuticals, agrochemicals, and other fine chemicals. Additionally, it has potential applications in the development of new materials and catalysts. PYRAZOLO[1,5-A]PYRIDINE-2-CARBALDEHYDE has attracted interest in the scientific community due to its versatile reactivity and potential for the creation of novel compounds with valuable properties.

InChI:InChI=1/C8H6N2O/c11-6-7-5-8-3-1-2-4-10(8)9-7/h1-6H

Upstream product

• 80537-14-0 ethyl pyrazolo<1,5-a>pyridine-2-carboxylate 
• 81803-59-0 ethyl 2-azido-3-(2-pyridyl)propenoate 
• 1121-60-4 pyridine-2-carbaldehyde 
• 76943-47-0 pyrazolo[1,5-a]pyridin-2-ylmethanol 
• 63237-87-6 pyrazolo[1,5-a]pyridine-2,3-dicarboxylic acid 
• 5825-71-8 pyrazolo<1,5-a>pyridine-2,3-dicarboxylic acid dimethyl ester 
• 25275-41-6 N-iminopyridinium ylide 
• 110-86-1 pyridine 
• 936546-67-7 pyrazolo[1,5-a]pyridine-2-carboxylic acid methoxy(methyl)amide 
• 63237-88-7 pyrazolo[1,5-a]pyridine-2-carboxylic acid 

Downstream Products

• 1016167-62-6 C₂₀H₂₃FN₄O 
• 1016167-61-5 C₂₀H₂₃FN₄O 
• 1016167-66-0 2-[4-(4-hydroxyphenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine 
• 1016167-59-1 C₁₇H₁₈FN₅ 
• 1016167-60-4 C₁₇H₁₈BrN₅ 
• 1428972-46-6 3-methoxy-N-(pyrazolo[1,5-a]pyridin-2-ylmethylene)aniline 
• 1428968-66-4 1-(1H-indol-3-yl)-2-((3-methoxyphenyl)amino)-2-(pyrazolo[1,5-a]pyridin-2-yl)ethan-1-one 
• 1373338-05-6 2-ethynylpyrazolo[1,5-a]pyridine 

Relevant articles and documents

COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF

The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).

SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

Synthesis, radiofluorination, and in vitro evaluation of pyrazolo[1,5-a]pyridine-based dopamine D4 receptor ligands: Discovery of an inverse agonist radioligand for PET

A series of fluoro-substituted analogs structurally derived from the aminomethyl-substituted pyrazolo[1,5-a]pyridine lead compounds 9 (FAUC 113) and 10 (FAUC 213) were synthesized and evaluated as high-affinity D4 receptor (D4R) ligands (3a-3h, Ki = 1.3-28 nM). The para-fluoroethoxy-substituted derivatives 3f and 3h revealed an outstanding D4 subtype selectivity of more than 3 orders of magnitude over both congeners D2 and D3 combined with inverse agonism at D4R. The corresponding 18F-labeled radioligands revealed high serum stability in vitro and log P values of 2-3. In vitro rat brain autoradiography showed specific binding of [18F]3h in distinct brain regions, including the gyrus dentate of the hippocampus, that were inhibited by both eticlopride (65-80%) and the selective D4R antagonist 10 (78-93%). The observed binding pattern was mainly consistent with the known D4R distribution in the rat brain. Thus, [18F]3h (FAUC F41) represents a potential radioligand for studying the D4R in vivo by positron emission tomography (PET).